NOT FOR INTRATHECAL USE

PACKAGING

Oxilan® 300 (ioxilan) Injection 62%, 300 mgI/mL
• 50 mL, 100 mL, 150 mL, 200 mL in cartons of
  10 single dose bottles
• 500 mL multi-dose bottles in cartons of 6

Oxilan® 350 (ioxilan) Injection 73%, 350 mgI/mL
• 50 mL, 100 mL, 150 mL, 200 mL in cartons of
  10 single dose bottles
• 500 mL multi-dose bottles in cartons of 6

PRESCRIBING INFORMATION
For complete information on Oxilan® please refer to the full Prescribing Information . For additional product related questions, please contact a Medical Liaison.

WARNINGS
Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to insure that this drug product is not administered intrathecally. Nonionic iodinated contrast media inhibit blood coagulation, in vitro, less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media. The use of plastic syringes in place of glass syringes has been reported to decrease but not eliminate the likelihood of in vitro clotting. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events.

ORDERING INFORMATION
For U.S. customers only. To request a sample or to order products please contact a Medical Center Professional. Please contact Guerbet Corporate office or an appropriate subsidiary if you are located outside the U.S.

Disclaimer